Human APOBEC3G-mediated hypermutation is associated with antiretroviral therapy failure in HIV-1 subtype C-infected individuals

Ujjwal Neogi§1,2, Anita Shet3, Pravat Nalini Sahoo3, Irene Bontelli1, Maria L Ekstrand4, Akhil C Banerjea5 and Anders Sonnerborg§6,1,6

‡Corresponding author: Ujjwal Neogi, Unit of Infectious Diseases, Department of Medicine, Huddinge, Karolinska Institutet, Stockholm, Sweden. Tel: +46-8585 81149 (ujjwal.neogi@ki.se); Anders Sonnerborg, Unit of Infectious Diseases, Department of Medicine, Karolinska Institutet, Stockholm, Sweden. Tel: +46-8585 81149 (anders.sonnerborg@ki.se)

Abstract

Introduction: Human APOBEC3G/F (hA3G/F) restricts retroviral replication through G-to-A hypermutations, which can generate drug-resistant progenies in vitro. The clinical relevance is still inconclusive. To bridge this gap, we aim to study the role of these hypermutations in evolution of drug resistance; we characterised hA3G/F-mediated hypermutations in the RT region of the pol gene of patients with or without antiretroviral therapy (ART).

Methods: In 88 HIV-1-positive individuals, drug resistance genotyping was carried out in plasma virus and provirus by population sequencing. Hypermutations were determined by three different approaches using Hypermut 2.0 software, cluster analysis and APOBEC3G-mediated defectives indices. Clinical and demographic characteristics of these individuals were studied in relation to these hypermutations.

Results: hA3G/F-mediated hypermutated sequences in proviral DNA, but not in plasma virus, were identified in 11.4% (10/88) subjects. Proviral hypermutations were observed more frequently in patients with ART failure than in ART-naïve individuals (p = 0.03). In therapy failure patients, proviral hypermutation were associated with greater intra-compartmental genetic diversity (p < 0.001). In therapy-naïve individuals, hypermutated proviral DNA with M184I and M230I mutations due to the editing of hA3G, had stop codons in the open reading frames and the same mutations were absent in the plasma virus. Only a limited concordance was found between the drug resistance mutations in plasma RNA and proviral DNA.

Conclusions: hA3G lethal hypermutation was significantly associated with ART failure in Indian HIV-1 subtype C patients. It is unlikely that viral variants, which exhibit hypermutated sequences and M184I and/or M230I, will mature and expand in vivo.

Keywords: APOBEC3G/F; hypermutation; drug resistance; antiretroviral therapy; India.

Introduction

The human apolipoprotein B mRNA-editing enzyme catalytic polypeptide-like 3G (APOBEC3G or hA3G) belongs to a family of at least 10 other proteins including hA3D, hA3F, hA3H which acts as a potent host restriction factor of retroviral replication through cytidine deaminase activity [1,2]. HIV-1 accessory protein vif interacts with hA3G and protects the virus from its anti-viral activity [3–5]. In the presence of defective vif, hA3G/F/D/H induces extensive dC-to-dU mutations in the minus strand of the single stranded DNA [6], consequently, dG-to-dA mutations in the plus strand of the cDNA [3,7]. Generally, hA3G restricts viral replication through lethal hypermutations by introducing stop codons into the open reading frame (ORFs) of the retroviral gene mainly in the tryptophan residue (TGG-to-TGA/TAA/ TAG). However, sub-lethal hypermutations have been suggested to contribute to the HIV-1 genetic diversity [8] and the low level of G-to-A mutation allows for greater genetic variations affecting HIV-1 evolution [9].

Cytidine deamination in the proviral sequences can generate drug-resistant progenies in vitro [10], though the in vivo consequences of hA3G/F are not well understood. Computer prediction of pol sequences has identified potential target sites for hA3G/F, but the role of hA3G in HIV-1 drug resistance in vivo is unknown and considered to be low [9]. Also, most of the previous in vivo studies used HIV-1 genes gag, env, vpu, and vif to identify hA3G induced hypermutations in proviral sequences [11–13]. Only a few studies have analysed the HIV-1 pol gene, which is a major target in antiretroviral therapy (ART) [14–16].

To bridge the gap between the in vitro observations and the limited knowledge about the in vivo consequences, we aimed to characterise the nature of hA3G/F-mediated hypermutations in the RT region of the pol gene in a
population of Indian HIV-1-positive patients, and its correlation with clinical and demographic parameters as well as with drug resistance.

**Methods**

**Patient populations**

Blood samples were collected in EDTA tubes (BD, USA) from 102 HIV-1-positive individuals who were participants of ongoing studies in southern India between November 2009 and October 2011. Among the 102 patients, both RNA virus and provirus were amplified in 86.2% (88/102), only RNA virus in 5.9% (6/102) and only provirus in 7.8% (8/102). Only paired sequences from both RNA virus and provirus (n = 88) were included in the study. Among these patients, 56 were ART naive and 32 were ART experienced at inclusion in the study (Table 1). In the treatment-experienced patients, the CD4+ T-cell values were < 250 cells/μl when ART was initiated, according to the Indian guidelines. The experienced patients were on first-line therapy with two nucleoside RT inhibitors (zidovudine or stavudine with lamivudine) and one non-nucleoside RT inhibitor (nevirapine or efavirenz). Routine CD4 + T-cells were measured with FACSCalibur system (BD, USA). Viral load was measured every sixth month by Abbott m2000rt system (Abbott Molecular Diagnostics, US). In the USA). Viral load was measured every sixth month by Abbott m2000rt system (Abbott Molecular Diagnostics, US). In the USA).

**PCR, proviral sequencing and subtyping**

Plasma HIV-1 RNA and proviral DNA from whole blood were extracted, amplified and sequenced, using an in-house genotyping assay as described previously [17,18]. In brief, a partial RT (17–235 aa) region of the pol gene was amplified from CDNA and proviral DNA, respectively, by conventional nested PCR. The purified nested PCR products were subjected to bidirectional population sequencing. Sequences were submitted to GeneBank with the following accession numbers: KC307783–KC307958.

HIV-1 subtyping was carried out using maximum likelihood phylogenetic analysis with best-fitted model for the dataset in MEGA 5.0 software [19]. Recombination was identified by the RIP 3.0 program available in Los Alamos Database (www.hiv.lanl.gov).

**Estimation of G-to-A substitutions**

To estimate G-to-A substitutions, proviral DNA sequences were aligned against the consensus Indian subtype C sequence [17]. The hA3G/F-mediated G-to-AG and G-to-AA scores, respectively, for each sequence were calculated [11]. The consolidated hA3G/F-mediated G-to-A hypermutation score was calculated as: [(Number of GG-to-AG or GA-to-AA substitutions/number of GG or GA in Indian consensus sequence)/(total number of mutations/sequence length)]. G-to-A preferences were calculated as described [11].

**Identification of hypermutated sequences**

Hypermut software was used to determine hA3G/F-mediated hypermutated sequences [20]. Further cluster analysis of preference for G-to-A substitutions relative to consolidated hA3G/F score and sequence analysis of 21 hA3G and 20 hA3F target sites in the 17–235 aa of the RT region identified by APOBEC3G-mediated defectives (A3GD) indices [21] were also used. Hypermutations were labelled into a dichotomous

---

**Table 1. Clinical and demographic data of all study subjects (n = 88) with hypermutated (n = 10) or non hypermutated (n = 78) proviral sequences**

| Parameter                  | All patients (n = 88) | Hypermutated (n = 10) | Non-hypermutated (n = 78) | P*       |
|----------------------------|-----------------------|-----------------------|---------------------------|----------|
| Age                        | 36 (30–41)            | 33 (29–37)            | 37 (30–42)                | 0.11**   |
| Sex male, No (%)           | 56 (63.6%)            | 7 (70%)               | 49 (62.8%)                | 0.74***  |
| Route of transmission      |                       |                       |                           |          |
| Heterosexual               | 69 (78.4%)            | 7 (70%)               | 62 (79.5%)                | 0.66***  |
| Perinatal                  | 15 (17%)              | 2 (20%)               | 13 (16.7%)                |          |
| Other/unknown              | 4 (4.5%)              | 1 (10%)               | 3 (3.8%)                  |          |
| CD4 T-cells/mm³            | 208 (117–363)         | 262 (154–485)         | 199 (98–356)              | 0.14**   |
| Median (IQR)               | 5.03 (0.86)           | 4.79 (0.75)           | 5.05 (0.88)               | 0.25**   |
| HIV RNA log_{10} copies/ml|                       |                       |                           |          |
| Mean (SD)                  | 32 (36.3%)            | 7 (70%)               | 25 (32.1%)                |          |
| Treatment, No (%)          | 56 (63.6%)            | 3 (30%)               | 53 (67.9%)                | 0.03***  |
| HIV-1 subtype              | C (98.9%) A1C (1.1%)   | C (100%)              | C (98.7%) A1C (1.3%)      |          |

CD4 T-cells and HIV RNA analysed at therapy failure in treatment experienced patients. The CD4 T-cells were < 250 cells/μl, when ART was initiated; all treated patients were given first-line therapy (zidovudine or stavudine with lamivudine and nevirapine or efavirenz).

*p values based on the comparison between patients with hypermutated versus non-hypermutated sequence; the percentage mentioned is the percentage of each subsets; **Mann–Whitney U Test; ***Fisher’s exact test.

Statistical significance (p < 0.05) is marked in bold letters.
variable if identified by one of the methods mentioned. Mutations were designated as lethal if there was stop codon in the ORFs.

Drug resistance mutations and nucleotide divergence
The World Health Organization (WHO) recommendations for surveillance of drug resistance mutations updated in the 2009 (SDRM_2009) list were used to define the transmitted drug resistance mutations in therapy-naïve patients [22]. Drug resistance mutations in therapy failure patients in the RT region (17–235 amino acids) listed in the December 2011 update from the International AIDS Society were considered [23]. The genetic distance of each of the sequences to the Indian consensus C sequence (intra-population divergence) and the intra-compartmental genetic diversity were calculated in MEGA 5 software [19].

Statistical analysis
Descriptive statistics were used to describe the characteristics of the patients. The demographic, clinical and viral genetic differences between hypermutated and non-hypermutated groups were evaluated by Mann-Whitney U Test and Fisher’s exact test. Spearman rank co-relation was used to find associations between different factors. The statistical analysis was calculated in SPSS software version 16.

Ethical approval
The study was approved by Institutional Ethical Review Board, St. John’s Medical College Hospital, Bangalore, India (IERB Study No. 153/2010). Written informed consent was obtained from all the adult participants and the caregivers of the children prior to recruitment, and a verbal assent was obtained from children older than nine years.

Results
Subtyping
Subtype C was identified in 98.9% (87/88) of the patients along with one A1C recombinant strain. Phylogenetic analysis using the sequences from both compartments verified the common origin of the strains in each individual.

Identification of hA3G-hypermutations
hA3G mediated hypermutated sequences in proviral DNA were identified in 11.4% (10/88) of the patients (Figure 1). However, the event of hypermutation was not detected in the plasma viral RNA. Among the clinical and demographic factors, only treatment failure was associated with hypermutation as compared to naïve patients (Table 1) ($p = 0.03$; Fisher’s exact test). Patients failing therapy had a 4.96-fold (OR; 95% CI; 1.18, 20.75) higher risk of lethal hypermutations than therapy-naïve patients. Among the six therapy-experienced patients whose samples were available before therapy, two had hypermutated proviral sequences at failure but not when they were therapy-naïve.

Association of G-to-A substitutions to clinical and demographic parameters in therapy-experienced patients
Among therapy-experienced patients, univariate analysis revealed no significant association with respect to patients’ clinical-demographic parameters and the presence of hypermutated or non-hypermutated sequences (Table 2). It is likely that the patients had reached their set point for viral load after failure and it did not differ between those with or without hypermutated sequences. A difference between the
hypermutated and non-hypermutated therapy-experienced groups was observed in the hA3G-specific G-to-A score ($p < 0.001$) and the intra-compartmental genetic diversity ($p < 0.001$), but not in the hA3F-specific G-to-A score (Table 2).

**Correlation between hA3G mediated hypermutation and viral heterogeneity**

When all of the patients were analysed, the consolidated hA3G specific G-to-A score was weakly associated with proviral divergence (Spearman rho = 0.24; $p = 0.02$), but not with plasma viral divergence. This correlation was found in the therapy-experienced patients only (Spearman rho = 0.57; $p = 0.001$), but not in the therapy-naive individuals.

**Mutations in computer derived hA3G/F motifs**

Among the hypermutated proviral DNA sequences, substitutions were observed in 31 aa residues, mainly in glycine and tryptophan (Figure 2). None of these mutations have been previously reported in HIV-1 subtype C, using Stanford Database HIVseq program. The three hypermutated proviral sequences from the therapy naive patients who had M184I and M230I drug resistance mutations and mutation in drug resistance position (M41I) also had stop codons in the RT ORF particularly at the tryptophan residue, which is the target site for hA3G.

**Drug resistance mutations**

Among the 56 treatment naïve patients, transmitted drug resistance mutations (DRM) were observed in both compartments of one patient giving the prevalence of transmitted drug resistance as 1.8% (1/56). One patient had D67DN and K70KE mutations in the proviral sequence. In one patient with hypermutated sequence, M184I was observed in the proviral sequence but not in plasma. Therefore, a high level of concordance in DR Genotyping (94.6%, 53/56) was observed in the therapy-naive individuals.

DRM were found in 84.4% (27/32) of the patients failing ART (Table 3). Exactly the same DRM in the RNA and DNA sequences were observed in 43.8% (14/32) of patients. As expected, among the NRTI and NNRTI mutations, M184I/V (71.9%), T215Y/F (34.4%), K103N (34.3%), and Y181C (28.1%) were the most prevalent in any of the compartments. This discrepancy was not only because of the hA3G restriction. Among the discordant sequence, only three (16.7%; 3/18) had hA3G associated hypermutations in their proviral sequences.

Important differences were found between the plasma RNA and the proviral DNA compartments. M184V and T215Y/F were observed in plasma only in six and three patients, respectively, while M41L and K65R were observed in one patient each in provirus only. Additional NRTI mutations were observed in 25% (8/32) of proviral and plasma viral sequences, respectively. Additional NNRTI mutations were found mainly in plasma (31.2%; 10/32) and to a lesser extent in proviral DNA (12.5%; 4/32). In two proviral sequences only, the E138K mutation was observed.

**Discussion**

In the present study, hA3G mediated lethal hypermutations were identified in the clinically important pol gene of proviral DNA from a minority (11.4%) of 88 Indian HIV-1 subtype C-infected patients. The hypermutations occurred more frequently in patients failing therapy than in therapy-naive patients. There was a correlation between their presence

| Table 2. Clinical, laboratory and viral genetic factors of the patients with ART failure |
|-----------------------------------------------|-----------------|-----------------|-----|
| Parameter                               | Hypermutated ($n = 7$) | Non-hypermutated ($n = 25$) | $p$ |
| Age                                     | 35 (23.5–36.5) | 38.5 (29–45) | 0.18* |
| Sex                                      | 5 (71.4%) | 17 (71%) | 0.98** |
| CD4 + T-cell count/mm$^3$                 | 278 (178–638) | 268 (172–404) | 0.54* |
| Viral load log$_{10}$ copies/ml          | 4.36 (4.19–4.96) | 4.27 (3.46–4.95) | 0.44* |
| Duration of ART                          | 12 (10–45) | 30 (14–38) | 0.51* |
| Consolidated scores mean (SD)             | hA3G G-to-A 7.72 (4.20) | 1.80 (0.94) | < 0.001* |
| Viral divergence mean (SD)                | hA3F G-to-A 2.70 (2.38) | 1.36 (0.74) | 0.21* |
| Proviral DNA                             | 0.09 (0.04) | 0.04 (0.01) | < 0.001* |
| Plasma RNA                               | 0.02 (0.01) | 0.03 (0.01) | 0.43* |
| Intra-compartmental genetic diversity    | Median (IQR) 0.05 (0.04–0.07) | 0.01 (0.007–0.014) | < 0.001* |

*Mann–Whitney U Test; **Fisher’s exact test.
and the proviral divergence, which is in line with the view that hA3G contributes to viral evolution.

*In vitro* studies and computer predictions have suggested a role of hA3G in the evolution of HIV drug resistance [9,10]. Thus, due to a suboptimal anti-APOBEC3G activity of HIV-1 Vif mutants, the HIV drug resistance mutations M184I [10,16] and E138K [16] may be induced *in vitro* without any drug exposure. Also, one study has reported the co-presence of M184I and E138K in 24% of hypermutated sequences of treated patients [16]. In contrast, co-evolution of M184I and E138K was not found in our hypermutated sequences. However, random polymorphisms of E138K/A were observed in the proviral DNA of both therapy-naive and experienced patients.

In addition to these *in vitro* results, differences have been reported on how often hA3G induced mutations can be found *in vivo*. When analysing HIV clones, hypermutated proviral DNA was detected in resting T-cells of all nine treated patients who had undetectable viremia, suggesting that the mutated viral genomes were able to integrate and persist in these cells [14]. In contrast, a minority (9.4%) out of 127 untreated subtype B infected mainly Caucasians exhibited such mutations at population based sequencing [13]. Furthermore, an even lower prevalence (4.8%) was found in 601 proviral DNA sequences of treated patients derived from a French database [16]. In our study, higher hypermutated proviral DNA was found in patients failing ART, but in naive patients the incidence was very low. Altogether, these data suggest that hA3G generated mutations are common but are mostly restricted to a minor viral population. However, it also seems possible that, in addition to the different techniques used, either clonal analysis or population based sequencing, the characteristics of patients studied might influence the extent hypermutations are found. Our data indicate that hypermutated proviral DNA accumulates in patients with therapy failure. This is further supported by the increase in intra-compartmental genetic diversity in patients with hypermutated proviral DNA as compared to those without. Also, in a re-analysis of earlier published sequences from India [24], we observed hA3G restriction in only two sequences of therapy-experienced patients. A recent study on five patients with long term successful treatment showed that these five patients harboured more in-frame stop codons in the proviral compartment compared to the therapy-naive patients [25], thus the effective ART may lead to the accumulation of the defective genomes in the reservoir [25].

No hypermutation in plasma HIV RNA was found. This is in line with the finding that the viruses released into plasma at low levels in nine patients on successful ART were devoid of hypermutated sequences [14]. This data is further strengthened by the observation from the Swedish InCare HIV cohort in which only three hypermutated RT sequences have been found after analyzing >2000 tested samples (unpublished data). As the hypermutated sequences with DRM (M184I; M230I) had stop codons in the ORFs and the absence of these DRMs in the plasma viral RNA, it is unlikely that such proviral variants will mature and expand *in vivo*. The presence of an increased number of hypermutated sequences in the therapy failure patients might be associated with decreased fitness of the virus due to the DRMs [26] as these strains might be superimposed by the more replication competent viruses compared to the less fit DRMs containing viruses after the treatment was initiated.

In addition to our analysis of hA3G mutations, we compared the sequences with regard to DRM. Transmitted drug resistance was uncommon which is concordant with previous findings [17,27]. For the failing patients, the DRM were expected [28,29]. However, we found a low level of concordance between the DRM in plasma and proviral DNA which is in line with the study of Chew et al. where DRM were more common in plasma [4]. In contrast, a study from...
Honduras showed 88% concordance between both compartments in heavily ART-treated patients [30].

The presence of drug resistance mutations like M184V, T215Y, K103N, and Y181C in plasma virus but not in the provirus in our study indicates that routine HIV RNA monitoring every six months and subsequent plasma viral genotyping at failure identifies the most recent viral populations circulating, although different sources of the two viral populations cannot be excluded. Therefore, in such a setting, testing of proviral DNA could possibly underestimate the true burden of recently developed resistant virus. However, the presence of key mutations in the proviral DNA which was not present in plasma is of importance for the selection of future ART regimen. World Health Organisation recommends the use of dried blood spot for transmitted drug resistance surveillance but not in patients undergoing therapy [31]. High concordance in the DR Genotyping in both compartments in therapy-naive patients corroborates the idea. It may solve the logistics challenges in countries where most of the part the cold chain transport is not available. Thus, although routine drug resistance testing is frequently not affordable in resource-poor settings, further studies are recommendable to evaluate which compartment to analyse, especially in patients on therapy.

Our study has some inadvertent caveats. First, the analysis is based on population sequencing and therefore

### Table 3. Drug resistance mutations in plasma RNA and proviral DNA in therapy-experienced patients

| Plasma virus | Provirus |
|--------------|----------|
| NRTI mutations | NNRTI mutations | NRTI mutations | NNRTI mutations | hA3G |
| 1 | M41L, D67N, K70R, M184V, T215Y, K219E | Y188L | M41L, D67N, K70R, V75I, M184V, T215Y, Y188L, M230I | Yes |
| 2 | D67N, T215Y, K219E | Y188L | D67N, K70R, M184V, T215Y, K219E, L100I, Y188L | |
| 3 | M184V | Y181C | M184V | Y181C |
| 4 | M184V, T215Y, K219Q | K103N, M230L | M184V, T215Y, K219Q, K103N, M230L | |
| 5 | None | V106A | None | V106A |
| 6 | M41L, D67N, K70R, M184V, T215Y | A98G, K101E, G190A | M41L, D67N, K70R, M184V, T215Y, A98G, K101E, G190A | |
| 7 | D67N, K70R, M184V, K219E | V106M, F227L | D67N, K70R, M184V, K219E | V106M, F227L |
| 8 | None | None | None | Yes |
| 9 | K70R, M184V, K219E | K103N, Y181C | K103N, Y181C | |
| 10 | M184V, T215Y | K101E, V108I, Y181C | None | None |
| 11 | None | None | None | Yes |
| 12 | M41L, L74V, M184V, L210W, T215Y | V108I, Y181C | M41L, L74V, M184V, V108I, Y181C | Yes |
| 13 | M184V, T215Y | A98G, K101E, G190A | None | A98G, G190A |
| 14 | D67N, K70R, M184V, K219E | K103N, M184V | M184V | K103N |
| 15 | M41L, M184V, T215F | A98G, K103N | M41L, M184V, T215F, A98G, K103N | |
| 16 | M184V | Y181C | None | M184V |
| 17 | M184V | Y181C | M184V | Y181C |
| 18 | M184V | K101E, V106M, G190A | K103N, M184V | M184V |
| 19 | M184V | K103N | K103N, M230I | Yes |
| 20 | None | None | None | Yes |
| 21 | None | None | None | Yes |
| 22 | None | None | None | Yes |
| 23 | None | None | None | Yes |
| 24 | M184V | K103N | M184V | K103N |
| 25 | M184V | K103N | None | None |
| 26 | M184V | K103N | None | None |
| 27 | M184V | K103N, Y181C | None | None |
| 28 | M41L, M184V, T215Y | K103N, Y181C | K103N, Y181C, M41L, L74V, M184V, T215Y | |
| 29 | None | None | None | Yes |
| 30 | None | None | None | Yes |
| 31 | None | None | None | Yes |
| 32 | M41L, D67N, M184V, L210W | A98G, K101E, V106IM, G190A | M41L, D67N, M184V, L210W, T215Y, A98G, K101E, G190A | |

Discordant mutations are marked bold.
does not detect any hypermutations in the minor quasispecies. Second, the number of therapy failure patients is low compared to the treatment naïve individuals. This is due to a low number of treatment failures in our settings because of high (\(>95\%\)) adherence. We have thus observed only 2.8% (9/323) of viral treatment failure with a median duration of four years of therapy who had initially suppressed viremia following the initiation of the therapy [32]. Third, we do not know to which extent the mutations were present before initiation of ART since the analysed longitudinal samples from six patients only before and after therapy. However, even in this small sample size, hypermutation developed during therapy failure in two subjects.

Conclusions

In conclusion, our study showed for the first time that hA3G lethal-hypermutation was associated with the use of treatment in Indian patients who failed ART. Though DRM were present in the hypermutated proviral compartment, all strains had a stop codon in its ORF. Therefore, it is unlikely that such viral variants will mature and expand in vivo which is supported by the absence of those mutations in plasma viral populations. However, further studies are required to validate the idea with appropriate in vitro cell culture models and with analysis of a large number of patients to gain the mechanistic view of the role of hA3G in the evolution of drug resistance and its clinical consequences. The evidence from this study also suggests the possible use of proviral drug resistance genotyping as an alternate to plasma viral genotyping for surveillance of transmitted drug resistance in resource-limited settings, specifically from the rural and remote part of the country where the logistics challenges remain.

Authors' affiliations

1Unit of Infectious Diseases, Department of Medicine, Karolinska Institutet, Stockholm, Sweden; 2Clinical Virology, Department of Microbiology, St. John’s Medical College, Bangalore, India; 3Department of Pediatrics, St. John’s Medical College Hospital, Bangalore, India; 4Department of Medicine; Center for AIDS Prevention Studies, University of California, San Francisco, CA; 5Virology, National Institute of Immunology, New Delhi, India; 6Division of Clinical Virology, Department of Laboratory Medicine, Karolinska University Hospital, Stockholm, Sweden

Competing interests

The authors declare that they have no competing interests.

Authors' contributions

UN, ACB and A. Sonnerborg conceived and designed the experiments. UN, PNS and IB performed the experiments. UN, PNS and IB analyzed the data. A. Shet, ACB and MLE contributed reagents/materials/analysis tools. UN and A. Sonnerborg wrote the paper. A. Shet, IB, ACB and MLE reviewed the paper. Patient recruitment and patients clinical data analyses were done by A. Shet and MLE.

Acknowledgements and funding

The work was supported by the Swedish Physicians against AIDS (FOa2011-0014), the European Union FP7 CHAIN Swedish Research Council and National Institute of Health (R01-MH07513). We thank the staff of the Infectious Disease Clinic, St. John’s Hospital, Bangalore, for assistance with patient recruitment. UN and AShet acknowledge Erasmus Mundus External Co-operation Window 13 (India) scholarship. The authors thank Karthika Arumugam, St. John’s Research Institute, and Elsa Heylen, UCSF, for their help with data support and statistics.

References

1. Sheehy AM, Gaddis NC, Choi JD, Malim MH. Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral vif protein. Nature. 2002;418(6898):646-50.
2. Resfälld EW, Hultquist JF, Harris RS. Endogenous origins of HIV-1 G-to-A hypermutation and restriction in the nonpermissive T cell line CEMzn. PLoS Pathog. 2012;8(7):e1002800.
3. Mangeat B, Turelli P, Caron G, Friedli M, Perrin L, Trono D. Broad antiretroviral defence by human APOBEC3G through lethal editing of nascent reverse transcripts. Nature. 2003;424(6944):99-103.
4. Chow CB, Potter SJ, Wang B, Wang YM, Shaw CO, Dwyer DE, et al. Assessment of drug resistance mutations in plasma and peripheral blood mononuclear cells at different plasma viral loads in patients receiving HAART. J Clin Virol. 2005;33(3):206-16.
5. Malim MH. Natural resistance to HIV infection: the viif-APOBEC interaction. C R Biol. 2006;329(11):871-5.
6. Yu Q, Kong R, Pillai S, Chiles K, Kearney M, Palmer S, et al. Single-strand specificity of APOBEC3G accounts for minus-strand deamination of the HIV genome. Nat Struct Mol Biol. 2004;11(5):435-42.
7. Zhang H, Yang B, Pomerantz RJ, Zhang CM, Arunachalam SC, Gao L. The cytidine deaminase CEM15 induces hypermutation in newly synthesized HIV-1 DNA. Nature. 2003;424(6944):94-8.
8. Sadler HA, Stenglein MD, Harris RS, Mansky LM. APOBEC3G contributes to HIV-1 variation through sublethal mutagenesis. J Virol. 2010;84(14):7396-404.
9. Jern P, Russell RA, Pathak VK, Coffin JM. Likely role of APOBEC3G-mediated G-to-A mutations in HIV-1 evolution and drug resistance. PLoS Pathog. 2009;5(4):e1000367.
10. Mulder LCF, Harari A, Simon V. Cytidine deamination induced HIV-1 drug resistance. Proc Natl Acad Sci U S A. 2008;105(14):5501-6.
11. Pace C, Keller J, Nolan D, James I, Gaudieri S, Moore C, et al. Population level analysis of human immunodeficiency virus type 1 hypermutation and its relationship with APOBEC3G and viif genetic variation. J Virol. 2006;80(18):9259-69.
12. Land AM, Ball TB, Luo M, Pilon R, Sandstrom P, Embree JE, et al. Human immunodeficiency virus (HIV) type 1 proviral hypermutation correlates with CD4 count in HIV-infected women from Kenya. J Virol. 2008;82(16):8172-82.
13. Ulenga NK, Barr AD, Hamel D, Sankale JL, Mboup S, Kanki PJ. The Level of APOBEC3G (hA3G)-related G-to-A mutations does not correlate with viral load in HIV type 1-infected individuals. AIDS Res Hum Retroviruses. 2008;24(10):1285-90.
14. Kieffer TL, Kwon P, Nettles RE, Han YF, Ray SC, Siliciano RF. G→A hypermutation in protease and reverse transcriptase regions of human immunodeficiency virus type 1 residing in resting CD4(+) T cells in vivo. J Virol. 2005;79(3):1975-80.
15. Amoedo ND, Afonso AO, Cunha SM, Oliveira RH, Machado ES, Soares MA. Expression of APOBEC3G/3F and G-to-A hypermutation levels in HIV-infected children with different profiles of disease progression. PLoS One. 2011;6(8):e24138.
16. Fourati S, Maliet S, Lambert S, Soulie C, Wirden M, Flandre P, et al. E138K mutation in the protease gene of HIV-1 is associated with sublethal mutagenesis and viral load in HIV type 1-infected individuals. AIDS Res Hum Retroviruses. 2008;24(10):1285-90.
17. Neogi U, Prarthana BS, Gupta S, D’Souza G, De Costa A, Kuttiatt VS, et al. Naturally occurring polymorphisms and primary drug resistance profile among antiretroviral-naive individuals in Bangalore, India. AIDS Res Hum Retroviruses. 2010;26(10):1097-101.
18. Neogi U, Bontell I, Shet A, De Costa A, Gupta S, Diwan V, et al. Molecular epidemiology of HIV-1 subtypes in India: origin and evolutionary history of the predominant subtype C. PLoS One. 2012;7(6):e39819.
19. Tamura K, Peterson D, Peterson N, Stecher G, Nei M, Kumar S. MEGA5: molecular evolutionary genetics analysis using maximum likelihood, evolutionary distance, and maximum parsimony methods. Mol Biol Evol. 2011;28(10):2731-9.
20. Rose PP, Korb BT. Detecting hypermutations in viral sequences with an emphasis on G→A hypermutation. Bioinformatics. 2000;16(4):400-1.
21. Gifford RJ, Rhee SY, Eriksson N, Liu TF, Kuclik M, Das AK, et al. Sequence typing by apolipoprotein B RNA-editing catalytic component-B and epidemiological surveillance of transmitted HIV-1 drug resistance. AIDS. 2008;22(22):3157-25.
22. Bennett DE, Camacho RJ, Otea De, Kuntzles DR, Fleyhe H, Kuclik M, et al. Drug resistance mutations for surveillance of transmitted HIV-1 drug resistance: update. PLoS One. 2009;4(3):e4724.
23. Johnson VA, Calvez V, Gunthard HF, Paredes R, Pillay D, Shafer R, et al. 2011 update of the drug resistance mutations in HIV-1. Top Antivir Med. 2011;19(4):156–64.

24. Sen S, Tripathy SP, Chimanpure VM, Patil AA, Bagul RD, Paranjape RS. Human immunodeficiency virus type 1 drug resistance mutations in peripheral blood mononuclear cell proviral DNA among antiretroviral treatment-naive and treatment-experienced patients from Pune, India. AIDS Res Hum Retroviruses. 2007;23(4):489–97.

25. Fourati S, Lambert-Niclot S, Soulie C, Malet I, Valantin MA, Descours B, et al. HIV-1 genome is often defective in PBMCs and rectal tissues after long-term HAART as a result of APOBEC3 editing and correlates with the size of reservoirs. J Antimicrob Chemother. 2012;67(10):2323–6.

26. Hu Z, Kuritzkes DR. Interaction of reverse transcriptase (RT) mutations conferring resistance to lamivudine and etravirine: effects on fitness and RT activity of human immunodeficiency virus type 1. J Virol. 2011;85(21):11309–14.

27. Neogi U, Sahoo PN, De Costa A, Shet A. High viremia and low level of transmitted drug resistance in anti-retroviral therapy-naive perinatally infected children and adolescents with HIV-1 subtype C infection. BMC Infect Dis. 2012;12(1):317.

28. Ekstrand ML, Shet A, Chandy S, Singh G, Shamsundar R, Madhavan V, et al. Suboptimal adherence associated with virological failure and resistance mutations to first-line highly active antiretroviral therapy (HAART) in Bangalore, India. Int Health. 2011;3(1):27–34.

29. Neogi U, Shet A, Shamsundar R, Ekstrand ML. Selection of nonnucleoside reverse transcriptase inhibitor-associated mutations in HIV-1 subtype C: evidence of etravirine cross-resistance. AIDS. 2011;25(8):1123–6.

30. Diallo K, Murillo WE, de Rivera IL, Albert J, Zhou Z, Nkengasong J, et al. Comparison of HIV-1 resistance profiles in plasma RNA versus PBMC DNA in heavily treated patients in Honduras, a resource-limited country. Int J Mol Epidemiol Genet. 2012;3(1):56–65.

31. Bennett DE, Myatt M, Bertagnolio S, Sutherland D, Gilks CF. Recommendations for surveillance of transmitted HIV drug resistance in countries scaling up antiretroviral treatment. Antivir Ther. 2008;13(Suppl 2):25–36.

32. Neogi U, Heylen E, Shet A, Chandy S, Shamsunder R, Sonnerborg A, et al. Long-term efficacy of first line antiretroviral therapy in Indian HIV-1 infected patients: a longitudinal cohort study. PLoS One. 2013;8(5):e65421.